| Quantity: | |
|---|---|
Extensive model portfolio – hapten, cytokine, allergen and vitamin D analog models covering acute, chronic and Th2/Th17/Th22 predominant AD endotypes.
Multiple species/strains – BALB/c (Th2 prone), C57BL/6 (Th1/Th17 prone) and SD rats available.
Composite endpoint – body weight, ear thickness, skin score, pruritus events, serum IgE, cytokine analysis (IL-4, IL-13, IL-17, IL-36), histopathology (HE, toluidine blue), epidermal thickness.
Translational Value – Ideal for testing JAK inhibitors, biologics (anti-IL-4Rα, anti-IL-13), PDE4 inhibitors and topical formulations.
IND Ready Packet – Research can be conducted in accordance with GLP principles.
DNCB induction C57BL/6 AD model
DNCB induces BALB/c mouse AD model
OXA induction C57BL/6 AD model
OXA-induced BALB/c AD model
MC903 induction C57BL/6 AD model
MC903 Inductive BALB/c AD Model
MC903&OXA induces AD model in BALB/c
FITC-induced BALB/c AD model
DNFB+OVA induces BALB/c AD model
IL-33-induced BALB/c AD model
IL-36 induces AD model in C57BL/6 mice
HDM+SEB induces AD model in C57BL/6 mice
• Efficacy testing of local and systemic AD therapies (JAK inhibitors, PDE4 inhibitors, biologics targeting IL-4/13, IL-31, IL-33, TSLP)
• Target validation of Th2, Th17, Th22 and itch pathways
• Biomarker discovery (IgE, cytokine signature, skin barrier proteins)
• Mechanism of action (MOA) studies
• Pharmacology and toxicology studies to support IND
scope | Specification |
Species/Strain | Mouse (BALB/c, C57BL/6); Rat (SD) |
induction method | Haptens (DNCB, OXA, DNFB+OVA, FITC), vitamin D analogs (MC903), cytokines (IL-33, IL-36), allergens (HDM+SEB), combinations (MC903+OXA) |
study time | 7–28 days (depending on model) |
critical endpoint | Body weight, ear thickness, skin clinical score, pruritus events (scratching), serum total IgE and antigen-specific IgE, cytokine levels (IL-4, IL-13, IL-17, IL-36, TNF-α), histopathology (H&E, toluidine blue), epidermal thickness, immune cell infiltration (FACS/IHC) |
packet | Raw data, analysis reports, clinical photos, histology slides, flow cytometry files, bioinformatics (optional) |
Q: How do I choose an appropriate AD model for my drug candidate?
A: Consider the mechanism of your drug: Th2-targeted biologics (eg, anti-IL-4Rα) are best evaluated in hapten or MC903 models; Th17-related compounds may be suitable in IL-36 or HDM+SEB models. BALB/c mice showed a stronger Th2 response, whereas C57BL/6 showed a more balanced Th1/Th17 profile. Our scientific team can guide model selection based on your specific goals.
Q: Can these models be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different dosing regimens, combination therapies)?
Answer: Of course. Our scientific team tailors induction protocols, treatment plans and endpoint analyzes for your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Most AD models are completed within 2-4 weeks, including sensitization/challenge and treatment phases. The exact timeline depends on model selection and endpoint.
